The CIBERER (Networked Biomedical Research Center for Rare Diseases) has incorporated two new research groups, among them the Pathogenesis of autoimmune neuronal disordersIDIBAPS group, led by Dr. Josep Dalmau. The other group that has joined the CIBERER is led by Dr. Vicente Vicente at the Instituto Murciano de Investigación Biosanitaria.
Dr. Josep Dalmau is an international leader in the study of neurology and psychiatry. In the last 7 years he has identified a total of eight autoimmune brain diseases. His group research is focused on a type of diseases related to autoimmunity, cancer and synaptic proteins. They have described novel syndromes and associated immune-mechanisms, isolated the target antigens, and developed diagnostic tests some of which are currently used around the world.
His group has discovered a new category of autoimmune diseases responsible for changes in memory, behavior, cognition and that can cause psychosis. The results of their studies have had a major impact in the field of neuroscience and multiple medical disciplines because they offer a connection between immunological processes and neural functions related to memory, behavior, psychosis, epilepsy and neuronal degeneration.
New CIBER incorporations
The Networked Biomedical Research Center (CIBER) has incorporated a total of 11 new research groups of excellence in fields such as nanotechnology, diabetes, respiratory disease, epidemiology, obesity, psychiatric disorders and rare diseases.
The Carlos III (ISCIII) Institute recently published the final resolution by which these groups will become part of the different CIBER thematic areas after being selected in an ISCIII call framed in the Strategic Action in Health in which participated 132 research groups.
“These 11 groups were selected from the 132 submitted for the excellence in their research and their suitability for networking and to strengthen the scientific leadership of our different thematic areas,” explains Manuel Sanchez, CIBER Manager.
Source: CIBERER
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Memo Therapeutics, a late-stage biotech company developing a best-in-c...
